Theravance Biopharma TBPH Income Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| $109.78M+68.2% | $107.46M+66.9% | $80.33M+27.1% | $77.21M+24.5% | $65.27M+6.1% | ||
| $31.79M-20.8% | $37.41M-0.6% | $39.51M+8.2% | $40.66M+14.4% | $40.13M+14.6% | ||
| $73M+3.1% | $73.65M+6.5% | $73.63M+11.3% | $72.18M+10.3% | $70.8M+4.7% | ||
| $108.43M-6.1% | $111.07M-0.2% | $113.14M+5.6% | $114.4M+10.1% | $115.44M+11.2% | ||
| $108.43M-6.1% | $111.07M-0.2% | $113.14M+5.6% | $114.4M+10.1% | $115.44M+11.2% | ||
| $1.35M+103% | -$3.6M+92.3% | -$32.81M+25.4% | -$37.2M+11.3% | -$50.18M-18.5% | ||
| 1.2%+78.1pp | -3.4%+69.6pp | -40.9%+28.8pp | -48.2%+19.4pp | -76.9%-8.1pp | ||
| —— | $2.46M-3.3% | $2.52M-0.2% | $2.58M+3.0% | $2.56M+5.4% | ||
| $12.25M+179% | $10.17M+108% | $7.44M+27.7% | $4.72M-23.9% | $4.39M-42.1% | ||
| $136.92M+383% | $129.25M+390% | $47.24M+216% | $40.08M+205% | -$48.35M-30.0% | ||
| $22.37M+124% | $23.35M+97.8% | $17.9M+105% | $27.05M+264% | $9.98M+31.7% | ||
| $114.54M+296% | $105.9M+288% | $29.34M+159% | $13.03M+129% | -$58.33M-30.3% | ||
| 104.3%+194pp | 98.5%+186pp | 36.5%+115pp | 16.9%+90.5pp | -89.4%-16.6pp | ||
| $2.20+286% | $2.03+277% | $0.57+156% | $0.24+126% | -$1.18-37.2% | ||
| $2.26+292% | $2.09+282% | $0.58+157% | $0.25+127% | -$1.18-37.2% | ||
| 205.4M+4.6% | 203.8M+4.6% | 201.2M-0.1% | 198.3M-3.1% | 196.3M-7.7% | ||
| 202.3M+3.0% | 200.7M+3.0% | 199.3M-1.1% | 197.8M-3.4% | 196.3M-7.7% | ||
| —— | —— | —— | —— | —— | ||
| —— | —— | —— | —— | —— | ||
| $12.25M+179% | $10.17M+108% | $7.44M+27.7% | $4.72M-23.9% | $4.39M-42.1% | ||
| $109.78M+68.2% | $107.46M+66.9% | $80.33M+27.1% | $77.21M+24.5% | $65.27M+6.1% | ||
| $1.35M+103% | -$3.6M+92.3% | -$32.81M+25.4% | -$37.2M+11.3% | -$50.18M-18.5% | ||
| $2.94M+106% | -$1.98M+95.6% | -$31.17M+26.3% | -$35.52M+11.7% | -$48.49M-19.7% | ||
| $2.94M+106% | -$1.98M+95.6% | -$31.17M+26.3% | -$35.52M+11.7% | -$48.49M-19.7% | ||
| 2.7%+77.0pp | -1.8%+68.4pp | -38.8%+28.2pp | -46%+18.9pp | -74.3%-8.4pp | ||
| $1.35M+103% | -$3.6M+92.3% | -$32.81M+25.4% | -$37.2M+11.3% | -$50.18M-18.5% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What is Theravance Biopharma's revenue?
- Theravance Biopharma (TBPH) generated $109.8M in revenue over the trailing twelve months, up 68.2% year over year.
- Is Theravance Biopharma profitable?
- Theravance Biopharma reported $114.5M in net income over the trailing twelve months, a 104.3% net margin.
- What are Theravance Biopharma's profit margins?
- Gross margin is 60.8% and operating margin is 1.2%, with a 104.3% net margin.
- What is Theravance Biopharma's earnings per share?
- Theravance Biopharma's diluted EPS over the trailing twelve months is $2.20.
- Where does Theravance Biopharma's income statement data come from?
- Every line is extracted from Theravance Biopharma's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
